

[Midazolam](#)

Essential medicine status

Section:

[2. Medicines for pain and palliative care](#) [2.3. Medicines for other common symptoms in palliative care](#)

ATC codes: [N05CD08](#)

EMLc

Indication

Palliative care ICD11 code: [QC7A](#)

INN

Midazolam

Medicine type

Chemical agent

List type

Core

Formulations

Oral > Liquid: 2 mg per mL (EMLc)

Parenteral > General injections > unspecified: 1 mg per mL in 5 mL vial ; 5 mg per mL in 1 mL vial ; 5 mg per mL in 3 mL vial

Local > Buccal > Solution: ; 5 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration) ; 5 mg per mL in 1 mL pre-filled syringe (for oromucosal administration) ; 5 mg per mL in 1.5 mL pre-filled syringe (for oromucosal administration) ; 5 mg per mL in 2 mL pre-filled syringe (for oromucosal administration) ; 10 mg per mL in 0.25 mL pre-filled syringe (for oromucosal administration) ; 10 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration) ; 10 mg per mL in 0.75 mL pre-filled syringe (for oromucosal administration) ; 10 mg per mL in 1 mL pre-filled syringe (for oromucosal administration)

Oral > Solid > dosage form: 7.5 mg (EML) ; 15 mg (EML)

EML status history

First added in 2009 ([TRS 958](#))

Changed in 2013 ([TRS 985](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Midazolam](#)

DrugBank

[Midazolam](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of midazolam solution for oral administration 5 mg/mL and 10 mg/mL to the EML and EMLc; - the deletion of midazolam solid oral dosage forms from the EMLc; - to modify the formulations descriptions of midazolam injection to better describe the available dosage forms.